Vir, GSK plan to seek emergency use nod for COVID-19 antibody therapy | Reuters(Reuters) –

Vir Biotechnology and Britain’s GSK said on Wednesday they planned to seek emergency use authorization (EUA) for their experimental COVID-19 antibody therapy after interim data from a study showed 85% reduction in hospitalization and deaths among patients. An independent panel recommended stopping further enrolment for the late-stage trial due to evidence of “profound efficacy” of the therapy, Vir and GSK said in a joint statement. Antibody treatments are designed to decrease the severity of COVID-19 among patients diagnosed with the infection. Additionally, the companies said a new laboratory study showed the therapy, VIR-7831, was equally effective against the UK, South African and Brazilian variants of the coronavirus. Vir and GSK announced a partnership last year to research COVID-19 treatments. #manchesterunited#manchestercity#HealthForAll#HealthBroadcastingService#QAnon#march72021#nba#arsenalfc #sacramentokings#losangeleslakers#HealthBroadcastingServiceInPublicHealthPartnership#leSamyn2021#gonzagabasketball#liverpoolfc#sanantoniospurs#deutscherwetterdienst#jonathantucker#meyersleonard#meganmarkle#ellemiekevermolen#sacramentokings#lasvegasraiders#piersmorgan#drwulienteh#washingtonwizard#birdsofafeatherpaulinequirke#vegasgoldenknights#urinarytractinfection#glasgowwarriors#memphiswizard#sixnationschampionship#jackiebradleyjr#momentswithannie #losangeleslakers #amazonfresh#gonzagabulldogs #freddieflintoff#losangelesclippers#simonbaker#googleboxhttps://www.reuters.com/…/us-health-coronavirus-gsk-vir…